Neurocloud SISCOM

Qubiotech
Automatic co-registration of the SPECT images with the patient's MRI. Interictal SPECT image subtraction is applied on the ictal image and the epileptogenic zone is identified. The SISCOM procedure is recommended by the EANM in the study of epilepsy, and provides high sensitivity and specificity in the localization of the epileptogenic focus. Neurocloud SISCOM provides a parametric map of the voxels identified as epileptogenic zone on MRI, data tables with the maximum Z-Score for each region of interest (ROI) as well as the percentage overlap of the focus and the SPECT - MRI fusion image.
qubiotech-neurocloud-siscom.png
Information source: Vendor
Last updated: Sept. 10, 2023

General Information

General
Product name Neurocloud SISCOM
Company Qubiotech
Subspeciality Neuro
Modality MR, SPECT
Disease targeted Epilepsy
Key-features Automatic co-registration SPECT-MRI, interictal SPECT subtraction ictal image, identification of epileptogenic focus, percentage overlap of the focus
Suggested use During: perception aid (prompting all abnormalities/results/heatmaps), interactive decision support (shows abnormalities/results only on demand), report suggestion

Technical Specifications

Data characteristics
Population Patients from 16 to 90 yo.
Input SPECT 3D Acquisition with 99mTc HMPAO, OSEM (recommended) or FBP reconstruction.
Input format DICOM
Output Co-registered SPECT-MRI, interictal SPECT substraction image, table with the maximum Z-Score, percentage overlap of the focus
Output format PDF, DICOM, NIFTI, EXCEL
Technology
Integration Integration in standard reading environment (PACS), Integration RIS (Radiological Information System), Integration via AI marketplace or distribution platform, Stand-alone webbased
Deployment Locally on dedicated hardware, Locally virtualized (virtual machine, docker), Cloud-based
Trigger for analysis On demand, triggered by a user through e.g. a button click, image upload, etc.
Processing time 1 - 10 minutes

Regulatory

Certification
CE
Certified, Class I , MDD
FDA No or not yet
Intended Use Statements
Intended use (according to CE) The Neurocloud SISCOM software is intended to perform the SISCOM analysis of ictal-interictal SPECT images. The two SPECT images are normalized in intensity and subtracted, as detailed in the previous bibliography on the SISCOM methodology. The MRI image is not modified or processed, and it is used only for anatomical reference. Neurocloud SISCOM is not an automatic diagnostic tool, and it is not intended to provide any diagnostic guess. Nor the software results nor the provided report are intended to provide a diagnosis. The results must be reviewed and validated by a Nuclear Medicine Physician, which is the intended user of the device.

Market

Market presence
On market since 01-2018
Distribution channels deepcOS, Alma AI MARKETPLACE
Countries present (clinical, non-research use) 2
Paying clinical customers (institutes)
Research/test users (institutes)
Pricing
Pricing model Pay-per-use, Subscription, Customizable plans
Based on Number of installations, Number of analyses, Customizable plans

Evidence

Evidence
Peer reviewed papers on performance
Non-peer reviewed papers on performance
Other relevant papers